(Adnkronos) - “Urgente coniugare innovazione e sostenibilità, per mantenere alti gli standard di cura per i pazienti con malattie infiammatorie croniche intestinali” (Mici) come la malattia di Crohn e la colite ulcerosa. È il messaggio degli esperti riuniti al XV Congresso nazionale Ig-Ibd, il Gruppo italiano per lo studio delle malattie infiammatorie croniche intestinali, in corso a Riccione.
Category
🗞
NewsTranscript
00:00More than 900 clinics, the most recent diagnostic, therapeutic and technological innovations,
00:12the new challenges for the future between innovation and sustainability.
00:15IGBD took the lead in the 15th National Congress, the three-day organized by the Italian Group
00:22for the Development of Inflammatory and Chronic Intestinal Diseases.
00:25We are witnessing a revolution in clinical practice, experts say,
00:29between advanced therapies, innovations and new smart technologies,
00:33such as artificial intelligence and telemonitoring.
00:37We know very well what are the problems related to costs,
00:42both from a pharmacological point of view and from an endoscopic point of view.
00:50All this must lead to a reflection on the approach that we must have in the management of our patients,
00:56with a particular eye to interdisciplinarity.
00:59All this in order to enhance a system that can also rationalize costs,
01:06but also increase the performance of our treatments,
01:11in trying to reach more and more the therapeutic objectives
01:16in the therapy of inflammatory and chronic intestinal diseases.
01:19Inflammatory and chronic intestinal diseases are a group of pathologies
01:23characterized by a chronic inflammation of the gastrointestinal tract
01:27with a significant impact on the life of patients.
01:30Although these diseases can occur at any age,
01:33they occur more frequently among adolescents and young adults under 35,
01:38with a quarter of the cases even already in the pediatric age.
01:42Clearly, in addition to the importance of having available new drugs,
01:46the strategies with which we use them are equally important.
01:49In the future, we hope to have available the so-called biomarkers,
01:53so that we can know if that patient will respond to that type of drug
01:59and that other patient to another type of drug.
02:01So we are always moving towards more personalized medicine,
02:05with the main aim of maintaining the sustainability of the system
02:10and trying to guarantee sustainability with the costs of these therapies.
02:14To date, there are still no certain Italian epidemiological data
02:18or precise estimates on the socioeconomic impact of inflammatory and chronic intestinal diseases.
02:23In our country it is estimated, I say it is estimated because we do not have precise numbers,
02:28that there are about 270-300 thousand patients affected by inflammatory and chronic intestinal diseases
02:34and about 7 million are patients who suffer from it in the world.
02:39In the course of the following decades,
02:41it is thought that we will add figures of 30 million,
02:45even 50 million patients affected by these diseases.
02:48A priority of the Foundation is precisely to collect data
02:52on the cases of Colitis Ulcerosa and Crohn's disease
02:56with the aim of having a photograph as precise as possible
02:59in terms of epidemiology and, but not only,
03:03of the clinical characteristics of the medical treatments and so on in our country.